Description
Aspirin has been investigated as a low-risk option to prevent recurrence in patients with unprovoked venous thromboembolism (VTE) after initial anticoagulant therapy. In a randomized trial of 822 patients, aspirin (100 mg daily) did not significantly reduce the recurrence of VTE compared to placebo. However, aspirin significantly lowered the risk of major vascular events including VTE, myocardial infarction, stroke, or cardiovascular death by 34%, and reduced the broader composite of vascular events and all-cause mortality by 33%. Bleeding risks and serious adverse events were similar between groups. These findings support aspirin’s potential benefit in reducing overall vascular risk following anticoagulation for unprovoked VTE.